Journal
ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY
Volume 128, Issue 4, Pages 875-879Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/13813455.2020.1734842
Keywords
Alzheimer's disease; microRNA; biomarker; serum
Funding
- Research & Technology Deputy, Hamadan University of Medical Sciences [9603302132]
Ask authors/readers for more resources
miR-106b may be a promising serum biomarker for early diagnosis of Alzheimer's disease.
Analysis of miRNAs has a strong potential for the identification of novel prognostic or predictive biomarkers in the serum of AD patients. In this study, we investigated the serum levels of miR-106b as a diagnostic biomarker for AD and evaluate its predictive value for therapeutic response to the drug rivastigmine. Patients were divided into either responding (n = 33) or non-responding (n = 23) groups according to rivastigmine treatment and to Mini-Mental State Exam score. The serum concentrations of miR-106b were measured with real-time PCR. Here, we found that miR-106b was significantly down-regulated in the serum samples of AD patients compared with those of controls (p < .001). ROC results showed a specificity of 62% and a sensitivity of 94%. The serum values of miR-106b tended to be positively associated with the therapeutic response but were not significant (p = .15). Taken together, detection of serum miR-106b might be a promising serum biomarker for early diagnosis of AD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available